Navigation Links
Immtech Reports Fiscal Second Quarter 2008 Results
Date:11/8/2007

NEW YORK, Nov. 8 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) today announced results for its fiscal second quarter ended September 30, 2007.

For the three months ended September 30, 2007, revenues were $1,030,000, as compared to $491,000 for the three months ended September 30, 2006. The increase was primarily attributable to revenues relating to a licensing agreement and research agreement. Loss from operations for the three months ended September 30, 2007 was $3,466,000, as compared to a loss from operations of $1,753,000 for the three months ended June 30, 2006. The three month period ended September 30, 2006 included a receivable of $1,874,000 relating to the Neurochem litigation award. Net loss attributable to common stockholders for the three months ended September 30, 2007 was $3,469,000, or $0.23 per share, compared to a loss of $1,758,000, or $0.13 per share, in the previous year.

At September 30, 2007, unrestricted cash and cash equivalents were $9,840,000 as compared to $12,462,000 at March 31, 2007. For the same periods, restricted funds on deposit were $694,000 and $3,119,000, respectively. Subsequent to September 30, 2007, a payment of $5,123,000 was received to further the development of pafuramidine, the Company's oral drug candidate, in the Phase III African sleeping sickness trial.

During the three-month period ended September 30, 2007, several significant milestones were achieved. In addition to the Par Pharmaceutical agreement, Immtech received orphan drug status from the USFDA for pafuramidine to treat malaria and African sleeping sickness, added a new board member and a strategic advisor to the team, and received from China's State Food and Drug Administra
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
3. Chinese SFDA Grants Immtech Fast Track Status
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
6. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Spherix Reports Second Quarter Earnings
9. Tapestry Reports Second Quarter 2007 Results
10. Callisto Reports on Second-Quarter 2007 Milestones
11. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Research and Markets  has announced the ... Product, End-user & by Lead Type - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The global ... segments, namely, holter monitor, resting, and stress type diagnostic ... million in 2013 and is poised to grow at ...
(Date:7/23/2014)... -- RT Oncology Services Corporation today announced that Craig ... directors. Mr. Mundie is currently senior advisor to the ... projects within the company and on technology strategy and ... officer. Mike Martin , president ... a visionary technology executive. His appointment is part of ...
(Date:7/23/2014)... July 23, 2014  Nonin Medical, Inc., the inventor ... medical monitoring, announced today that Mark VanderWerf , ... elected Chairman of the American Telemedicine Association,s (ATA) Industry ... The ATA is the leading international resource ... technologies. The ATA and its diverse membership work to ...
Breaking Medicine Technology:Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3Nonin Medical Announces that Mark VanderWerf has been Elected Chairman of the American Telemedicine Association's Industry Council 2
... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... on developing topically administered products using its proprietary transdermal ... exploring strategic alternatives aimed at enhancing shareholder value with ... Advisors, a division of KEMA Partners.  The goal ...
... 31, 2011 Nephros, Inc. (OTC Bulletin Board: ... marketing filtration products for therapeutic applications, infection control, and ... Form S-1 for its previously announced rights offering to ... 2011 by the Securities and Exchange Commission. ...
Cached Medicine Technology:Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4
(Date:7/23/2014)... 23, 2014 The American Telemedicine ... ATA’s twentieth annual meeting and tradeshow focused exclusively ... to attract over 5,000 attendees and more than ... May 3-5, 2015, in Los Angeles. , ATA’s ... technology professionals from researchers, clinicians, hospital and university ...
(Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
(Date:7/23/2014)... not be the sole domain of humans, with new ... comes to the love of their master. When ... stuffed dog, the real puppies in the study responded ... researchers from the University of California, San Diego (UCSD). ... attending to the stuffed dog and not when they ...
(Date:7/23/2014)... research on human cancer genes have been focused on ... to be translated in the form of amino acids ... a regulatory region or activator which controls the expression ... little was known of the role exerted such DNA ... today in Nature in collaboration with the ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 CarePoint Health ... first hospital in New Jersey to receive the da ... robotics platform in the da Vinci series. This 4th ... profound step forward in innovation. The intuitive da Vinci ... a wide spectrum of minimally invasive and complex surgical ...
Breaking Medicine News(10 mins):Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Dogs Can Get Jealous, Too 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4
... to provide guidance for global market development.SUNNYVALE, Calif. ... Systems, Inc., a technology leader in developing novel ... of Hironori Yamamoto, MD, PhD, of Jichi Medical ... privileged that Dr. Yamamoto has elected to join ...
... Other Health Insurers Are Illegally Denying Treatment to Autistic ... being released by Consumer Watchdog: Who: Guillermo Arce , ... father of Frank Nagle , Harvey Rosenfield ... insurance reform initiative, Proposition 103 , Scott Glovsky ...
... how autoimmune diseases are triggered , , TUESDAY, Feb. ... by exposure to pig brains might help researchers learn ... More than a year ago, workers at pork processing ... and tingling in their arms and legs. Their common ...
... MDVN ) today announced that it will ... on Wednesday, February 25, at 4:30 p.m. Eastern Time ... ongoing Phase 1-2 clinical trial of the Company,s novel ... Scher, M.D., principal investigator of the trial and chief ...
... TrinityCare Senior Living, Inc. (formerly OTCBB: JKAN) (the ... facilities, today announced that its Board of Directors has ... the public entity from July 31st to December 31st. ... and re-incorporation was completed and approved on February 16, ...
... HARRISBURG, Pa., Feb. 24 Swiss Villa Dairy Farm ... monocytogenes contamination and resumed sales of raw milk on ... milk is milk that has not been pasteurized. ... have samples of their milk laboratory tested due to ...
Cached Medicine News:Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 2Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 3Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 4Health News:Parents of Autistic Children Fight Back - Warn HMO Regulator Against Changing Rules to Favor Insurers That Deny Access to Medical Treatment 2Health News:Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients 2Health News:TrinityCare Senior Living, Inc. Changes Fiscal Year End to December 31st 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: